OCT

FDA Grants AI-Powered Notal Vision Home OCT "SCANLY" De Novo Marketing Authorization

Retrieved on: 
Donnerstag, Mai 16, 2024
Cloud, Insurance, Patient, Retina, Doctor of Philosophy, HRS, NOA, AMD, Neovascularization, Medicare, Health, Randomized controlled trial, OCT, Retinal, FDA, Digital, CPT, Disease, MD, De novo, Biomarker, Physician, Artificial intelligence, Home, TRO, Ophthalmology, Medical imaging

First-ever home retinal imaging service to monitor wet AMD, the leading cause of blindness for older patients

Key Points: 
  • Manassas, Virginia--(Newsfile Corp. - May 16, 2024) - Digital healthcare provider, Notal Vision, announced today that the US Food and Drug Administration (FDA) has granted De Novo authorization for its patient self-operated SCANLY® Home OCT device.
  • SCANLY captures spectral-domain optical coherence tomography (OCT) images in a 10 by 10-degree area centered on the point of fixation.
  • The proprietary, artificial intelligence (AI)-based Notal OCT Analyzer (NOA) segments and estimates the volume of hypo-reflective spaces (HRS)-important biomarkers in managing nvAMD-on OCT images.
  • Notal Vision's SCANLY Home OCT has the potential to support current and future advances in retinal disease management.

CACI Sets Another Distance Record for Optical Communications

Retrieved on: 
Donnerstag, Mai 23, 2024
Software, Mobile, Wireless, Networks, Contracts, Technology, Defense, Security, Satellite, Government Technology, Aerospace, Manufacturing, Telecommunications, OEM, NASA, OCT, Government, Deep Space Optical Communications, DSOC, CACI, Associate professor, Jet Propulsion Laboratory, LEO, Multimedia, Communications satellite

Using CACI International Inc’s ( NYSE: CACI ) optical communications technology, NASA successfully sent data from its Psyche spacecraft to the Jet Propulsion Laboratory in Southern California, a distance of more than 200 million kilometers, as part of the Deep Space Optical Communications (DSOC) experiment.

Key Points: 
  • Using CACI International Inc’s ( NYSE: CACI ) optical communications technology, NASA successfully sent data from its Psyche spacecraft to the Jet Propulsion Laboratory in Southern California, a distance of more than 200 million kilometers, as part of the Deep Space Optical Communications (DSOC) experiment.
  • Additionally, NASA will continue to leverage CACI’s optical technology for DSOC as the range is extended.
  • View the full release here: https://www.businesswire.com/news/home/20240523496661/en/
    “With this latest accomplishment, we have achieved another ‘first for mankind’ milestone with our technology,” said John Mengucci , CACI President and Chief Executive Officer.
  • “Our proven optical technology continues to attain historic milestones in the Optical Communications Terminal (OCT) realm.

EuroPCR 2024: Primary Outcomes from PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact Intravascular Lithotripsy System for Calcium Fragmentation in Moderate to Severe Calcified Coronary Artery Lesions

Retrieved on: 
Donnerstag, Mai 16, 2024
Health, Medical Devices, Health Technology, Clinical Trials, Research, Science, Cardiology, Elixir, Patient, Cardiovascular disease, Calcification, Learning curve, Fracture, OCT, Calcium, Effectiveness, MACE, Safety, Radiation, Ageing, PINNACLE, TRX, Physics, Workflow, Applied mechanics, PCI, IVL, Medicine, Medical imaging

Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE).

Key Points: 
  • Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE).
  • The data were presented at an innovation session at EuroPCR 2024 in Paris.
  • The novel LithiX Hertz Contact IVL system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal stent expansion.
  • The system incorporates plurality of small metal hemispheres on a flexible balloon designed to provide multiple discrete contact points with the calcium.

Spryte Medical Announces First Human Use of Novel Intravascular Brain Imaging Technology, Published in Science Translational Medicine

Retrieved on: 
Mittwoch, Mai 15, 2024
Research, Technology, Medical Devices, Neurology, Health Technology, Radiology, General Health, Health, Science, Artificial Intelligence, Blood, Patient, Cerebrovascular disease, University of Massachusetts, X-ray, AAAS, OCT, University, Stroke, Science Translational Medicine, MD, AI, Anatomy, Cerebral arteries, Pathology, University of Toronto, Workflow, Medicine, Professor, Hospital, Brain, Physician, Angiography, Multimedia, Noct, Medical imaging

The device is not approved for human use in the USA or commercially available.

Key Points: 
  • The device is not approved for human use in the USA or commercially available.
  • “The Spryte nOCT technology is an imaging probe, sized like a guidewire, that navigates seamlessly through the brain vessels using our usual neuro-interventional techniques.
  • Science Translational Medicine is a perfect journal to showcase this work, bringing together scientific innovation and medical application.
  • “This study provides proof of concept for using optical coherence tomography devices to better understand cerebrovascular pathology and intervention for a range of conditions in the human brain,” said editor Brandon Berry from Science Translational Medicine.

$6.1 Billion Optometry Equipment (OCT, Ophthalmoscope, Autorefractor, Tonometer, Slitlamp, Wavefront Analyzer) Market Analysis - Global Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Montag, Mai 13, 2024
Optical, Health, Medical Devices, Region, USD, Prevalence, OCT, Diagnosis, Canon Inc., Government, Retina, GCC, Ageing, Growth, Ophthalmoscopy, EssilorLuxottica, Optometry, Health care

Adoption of diagnostic tests is required for accurate diagnosis and treatment of various ailments, which is fueling the market expansion for optometry equipment.

Key Points: 
  • Adoption of diagnostic tests is required for accurate diagnosis and treatment of various ailments, which is fueling the market expansion for optometry equipment.
  • Over the course of the forecast period, the optometry equipment market is anticipated to develop at the fastest rate in the Asia Pacific region.
  • By application, the general examination category held the biggest proportion of the global optometry equipment market in 2023.
  • The sector that held the biggest share of the global optometry equipment market in 2023 was clinics.

Canadian seniors at risk of vision loss due to financial barriers, according to Specsavers survey

Retrieved on: 
Dienstag, Mai 14, 2024
Insurance, Specsavers, Prescription, AMD, Optometry, Risk, OCT, Optical coherence tomography, Glaucoma, Health, Leger, Incidence, Vance DeGeneres, Eye, Quality of life, Paratriathlon

Optometrists are equipped to detect the earliest signs of eye diseases," says Naomi Barber, Clinical Services Director at Specsavers.

Key Points: 
  • Optometrists are equipped to detect the earliest signs of eye diseases," says Naomi Barber, Clinical Services Director at Specsavers.
  • When examining the factors putting seniors' vision at risk, half do not have vision health benefits and one-in-four have skipped or delayed updating their eyewear prescriptions due to financial barriers.
  • Regular eye exams are important as 75 per cent of vision loss is preventable and treatable.1
    "We believe that Canadian seniors deserve better.
  • 1 A Report Card on Vision Health in Canada, The Canadian Council of the Blind and Fighting Blindness Canada.

NEC and Skyloom to Pioneer 100 Gbps Space Optical Communications, Transforming Global Internet Connectivity

Retrieved on: 
Mittwoch, März 20, 2024
Constellation, NEC, Communication, Partnership, Artificial intelligence, Orbit, History, Intelligence, Entrepreneurship, OCT, Radio, Data-rate units, Communications satellite

"This marks a monumental milestone in global internet and space communications," said Eric Moltzau, Chief Commercial Officer of Skyloom.

Key Points: 
  • "This marks a monumental milestone in global internet and space communications," said Eric Moltzau, Chief Commercial Officer of Skyloom.
  • "In partnership with NEC, we are committed to the joint development, testing, and manufacturing of the groundbreaking 100 Gbps WARP Optical Communications Terminal (OCT), slated for completion by the end of 2025.
  • In anticipation of this demand growth, NEC and Skyloom are at the forefront of developing technology to achieve optical communication speeds of 100 Gbps and higher.
  • "We expect that our collaboration with Skyloom on space optical communication will contribute to expanding space utilization in the era of networked satellite constellations."

EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

Retrieved on: 
Dienstag, Mai 7, 2024
Optical coherence tomography, Șaeș, Patient, Retinitis pigmentosa, Safety, Research, PDE6B, Paratriathlon, Chorioretinitis, Visual impairment, Natural history, Disease, OCT, Snellen, Eye, GVF, ARVO, Visual acuity, Ageing, Pharmaceutical industry

These data were reported during an oral presentation* on May 6, at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, US.

Key Points: 
  • These data were reported during an oral presentation* on May 6, at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, US.
  • The positive 24-month follow-up data presented confirm results from the previous interim analysis of the trial conducted at the 12-month follow-up point and support preparation for a registrational trial for HORA-PDE6b in PDE6b RP patients.
  • Further discussions with health authorities in the US and Europe are planned to define the optimal path to making HORA-PDE6b available to PDE6b RP patients.
  • The treatment was administered in the more affected eye while the other eye served as an untreated control.

Eye2Gene and Heidelberg Engineering Announce Collaborative Partnership at ARVO 2024

Retrieved on: 
Dienstag, Mai 7, 2024
Research, General Health, Optical, Apps, Applications, Medical Devices, Technology, Artificial Intelligence, Genetics, Science, Other Technology, Other Science, Health, Retina, AI, NIHR, Partnership, Artificial intelligence, Similarity, Infrared, OCT, Patient, DSM-IV codes, Data set, Annual general meeting, Medicine, Moorfields Eye Hospital, ARVO, Deep learning

Eye2Gene™ , a pioneering artificial intelligence National Institute for Health and Care Research (NIHR) funded project based at the University College London Institute of Ophthalmology and Moorfields Eye Hospital, and Heidelberg Engineering , a global leader in ophthalmic imaging and data technologies, are thrilled to announce their collaborative partnership, set to be unveiled at the ARVO 2024 Annual Meeting in Seattle.

Key Points: 
  • Eye2Gene™ , a pioneering artificial intelligence National Institute for Health and Care Research (NIHR) funded project based at the University College London Institute of Ophthalmology and Moorfields Eye Hospital, and Heidelberg Engineering , a global leader in ophthalmic imaging and data technologies, are thrilled to announce their collaborative partnership, set to be unveiled at the ARVO 2024 Annual Meeting in Seattle.
  • By combining Eye2Gene's cutting-edge artificial intelligence algorithm with Heidelberg Engineering image quality and innovative workflow solutions, the partnership aims to revolutionize the care pathway for patients with inherited retinal disease.
  • At ARVO 2024, attendees can experience firsthand the power of this collaboration at Stand #1905 and learn more about the collaborative partnership between Eye2Gene and Heidelberg Engineering.
  • "Because inherited diseases are rare, they are challenging to diagnose for most non-specialists," said Nikolas Pontikos, lead researcher for Eye2Gene.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
Montag, Mai 6, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Research, Genetics, Science, Clinical Trials, AMD, Patient, Cell, MM2, Geographic atrophy, MD, Doctor of Philosophy, OCT, Lineage, Paratriathlon, Degenerative disease, RPE, Atrophy, Therapy, Visual impairment, ELM

The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .

Key Points: 
  • The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD.
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.